Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease

Rhea-AI Summary

Vor Bio (Nasdaq: VOR) will host a live webcast to present newly disclosed, late-breaking 48-week Phase 3 clinical data in China for telitacicept in primary Sjögren’s disease.

The study was conducted by collaborator RemeGen. Vor Bio management and Ronald van Vollenhoven, M.D., Ph.D., Professor of Rheumatology at Amsterdam University Medical Center, will review key efficacy and safety results.

Webcast: Tuesday, October 28, 2025 at 4:30 PM Eastern Time. Registration options include listen-only and listen-with-live Q&A links; a replay will be posted at https://ir.vorbio.com/events-presentations/ approximately two hours after the call and will remain available for 30 days.

CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a live webcast to present and discuss the newly disclosed, late-breaking 48-week Phase 3 clinical data in China for telitacicept in primary Sjögren’s disease. The study was conducted by Vor Bio’s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331).

During the webcast, Vor Bio management, joined by Ronald van Vollenhoven, M.D., Ph.D., Professor of Rheumatology at Amsterdam University Medical Center, will review key efficacy and safety results from the trial.

Webcast Details:

Date: Tuesday, October 28, 2025
Time: 4:30 PM Eastern Time

Access: 

• Listen Only: Listeners can register for the webcast via this LINK
• Listen and Live Q&A: Analysts or investors wishing to participate in the Q&A session should use this LINK
  
  

Replay: A replay of the webcast will be available via the investor section of the Company’s website at https://ir.vorbio.com/events-presentations/ approximately two hours after the call’s conclusion and will remain available for a period of 30 days.

About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.

Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com

Sarah Spencer
investors@vorbio.com

FAQ

When will Vor Bio (VOR) present the China Phase 3 telitacicept data?

Vor Bio will webcast the presentation on October 28, 2025 at 4:30 PM ET.

What data will Vor Bio discuss during the October 28, 2025 VOR webcast?

Management will review newly disclosed, late-breaking 48-week Phase 3 clinical efficacy and safety results for telitacicept in primary Sjögren’s disease.

Who will join Vor Bio's webcast to discuss the telitacicept Phase 3 results?

Vor Bio management will be joined by Ronald van Vollenhoven, M.D., Ph.D., Professor of Rheumatology at Amsterdam University Medical Center.

How can investors register to listen or ask questions during the VOR webcast?

Registration links are provided for listen-only access and a separate link for listen plus live Q&A for analysts and investors.

Will Vor Bio post a replay of the October 28, 2025 webcast for VOR investors?

Yes. A replay will be available at https://ir.vorbio.com/events-presentations/ about two hours after the call and will remain accessible for 30 days.

Which company conducted the China Phase 3 telitacicept study discussed by Vor Bio (VOR)?

The study was conducted by Vor Bio's collaborator RemeGen.